Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

230
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
230
Genetic Screens02:46

Genetic Screens

5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

455
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
455
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

163
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
163
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

273
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
273

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomimetic model for the identification of distinctive microenvironmental factors in glioblastoma radiosensitivity.

Clinical and translational radiation oncology·2026
Same author

Prediction of Mesenchymal Stromal Cell Immune Suppression Using Live Imaging in a Three-Dimensional Microfluidic Device.

ACS biomaterials science & engineering·2026
Same author

Reciprocal Macrophage-MSC Crosstalk Drives Immunomodulatory and Regenerative Phenotypes in a Mineralized Collagen Scaffold.

Journal of biomedical materials research. Part A·2026
Same author

A microgel bone marrow model of mesenchymal stromal cell paracrine signaling supporting hematopoietic stem cell retention.

Acta biomaterialia·2026
Same author

An interfacial hydrogel compartment within a multicompartment tendon-to-bone scaffold influences cell behavior under cyclic tensile loading.

Regenerative biomaterials·2026
Same author

Mineralized collagen scaffold pore architecture and glycosaminoglycan content biases anti-inflammatory macrophage phenotype.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Feb 10, 2026

Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening
10:49

Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening

Published on: January 10, 2025

1.4K

Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform.

Brittany A Payan1, Annika Carrillo Diaz De Leon1, Tejasvi Anand2

  • 1Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.

Journal of Biomedical Materials Research. Part A
|February 9, 2026
PubMed
Summary

Researchers developed a novel microgel method to culture glioblastoma (GBM) cells, enabling faster drug screening. This 3D model mimics tumor environments, accelerating the search for new glioblastoma treatments.

Keywords:
drug screeningglioblastomamicrogel

More Related Videos

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells
08:35

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells

Published on: August 24, 2018

13.6K
Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.7K

Related Experiment Videos

Last Updated: Feb 10, 2026

Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening
10:49

Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening

Published on: January 10, 2025

1.4K
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells
08:35

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells

Published on: August 24, 2018

13.6K
Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.7K

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Drug Discovery

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
  • Current treatments like surgery and temozolomide (TMZ) face challenges due to drug resistance and recurrence.
  • There is a critical need for advanced models to accelerate the development of new GBM therapies.

Purpose of the Study:

  • To establish a microgel-based culture system for glioblastoma (GBM) cells.
  • To evaluate the utility of microgels for drug screening and therapeutic response assessment.
  • To enable high-throughput screening of potential GBM treatments.

Main Methods:

  • Encapsulation of GBM cells within gelatin and polyethylene glycol (PEG) microgels.
  • Assessment of microgel composition effects on cell morphology and metabolic activity.
  • Quantification of TMZ drug response in microgel cultures.
  • Integration of microgels with liquid handling systems for high-throughput screening.

Main Results:

  • Microgel composition influences GBM cell morphology.
  • GBM cells maintain metabolic activity and exhibit predictable drug response kinetics in microgels.
  • The microgel system effectively quantifies responses to single and metronomic TMZ dosing.
  • Microgels are compatible with liquid handlers for automated, high-throughput drug screening.

Conclusions:

  • Microgels provide a tailorable 3D environment for culturing GBM cells.
  • This microgel platform facilitates physiologically relevant drug screening and accelerates therapeutic discovery for glioblastoma.
  • The developed method supports high-throughput screening, addressing the urgent need for new GBM treatments.